[go: up one dir, main page]

JO3006B1 - املاح ليسين مبتكرة من مشتقات حامض 4-((فينوكسي الكيل)ثيو) فينوكسي الخليك - Google Patents

املاح ليسين مبتكرة من مشتقات حامض 4-((فينوكسي الكيل)ثيو) فينوكسي الخليك

Info

Publication number
JO3006B1
JO3006B1 JOP/2006/0300A JOP20060300A JO3006B1 JO 3006 B1 JO3006 B1 JO 3006B1 JO P20060300 A JOP20060300 A JO P20060300A JO 3006 B1 JO3006 B1 JO 3006B1
Authority
JO
Jordan
Prior art keywords
phenoxy
thio
lysine salts
acetic acid
acid derivatives
Prior art date
Application number
JOP/2006/0300A
Other languages
English (en)
Inventor
F Abdel-Magid Ahmed
Roessler Armin
Mehrman Steven
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Application granted granted Critical
Publication of JO3006B1 publication Critical patent/JO3006B1/ar

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
    • C07C323/51—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C323/56—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/10—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C323/18—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and singly-bound oxygen atoms bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton
    • C07C323/20—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and singly-bound oxygen atoms bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton with singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/04—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C229/26—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having more than one amino group bound to the carbon skeleton, e.g. lysine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C321/00—Thiols, sulfides, hydropolysulfides or polysulfides
    • C07C321/24—Thiols, sulfides, hydropolysulfides, or polysulfides having thio groups bound to carbon atoms of six-membered aromatic rings
    • C07C321/28—Sulfides, hydropolysulfides, or polysulfides having thio groups bound to carbon atoms of six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C53/00—Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen
    • C07C53/08—Acetic acid
    • C07C53/10—Salts thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/58—Unsaturated compounds containing ether groups, groups, groups, or groups
    • C07C59/64—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings
    • C07C59/66—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings the non-carboxylic part of the ether containing six-membered aromatic rings
    • C07C59/68—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings the non-carboxylic part of the ether containing six-membered aromatic rings the oxygen atom of the ether group being bound to a non-condensed six-membered aromatic ring
    • C07C59/70—Ethers of hydroxy-acetic acid, e.g. substitutes on the ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/58—Unsaturated compounds containing ether groups, groups, groups, or groups
    • C07C59/72—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings and other rings

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

يتعلق الاختراع الحالي باملاح ليسين مبتكرة وتركيبات صيدلانية تحتويها واستعمالها في معالجة خلل وحالات يتوسطها بي بي ايه ار دلتا.كما يتعلق الاختراع الحالي بعملية مبتكرة لتحضير أملاح الليسين المذكورة.
JOP/2006/0300A 2005-09-14 2006-09-07 املاح ليسين مبتكرة من مشتقات حامض 4-((فينوكسي الكيل)ثيو) فينوكسي الخليك JO3006B1 (ar)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US71713705P 2005-09-14 2005-09-14

Publications (1)

Publication Number Publication Date
JO3006B1 true JO3006B1 (ar) 2016-09-05

Family

ID=37865545

Family Applications (1)

Application Number Title Priority Date Filing Date
JOP/2006/0300A JO3006B1 (ar) 2005-09-14 2006-09-07 املاح ليسين مبتكرة من مشتقات حامض 4-((فينوكسي الكيل)ثيو) فينوكسي الخليك

Country Status (24)

Country Link
US (2) US7709682B2 (ar)
EP (1) EP1937065B1 (ar)
JP (1) JP5467770B2 (ar)
KR (5) KR20150013952A (ar)
CN (1) CN101304656B (ar)
AR (1) AR058044A1 (ar)
AU (1) AU2006291006B2 (ar)
BR (1) BRPI0615835B8 (ar)
CA (1) CA2622722C (ar)
DK (1) DK1937065T3 (ar)
ES (1) ES2535427T3 (ar)
GT (1) GT200600420A (ar)
HK (1) HK1122699A1 (ar)
HN (1) HN2006032171A (ar)
HU (1) HUE025185T2 (ar)
JO (1) JO3006B1 (ar)
NZ (1) NZ566504A (ar)
PE (1) PE20070434A1 (ar)
PL (1) PL1937065T3 (ar)
PT (1) PT1937065E (ar)
SI (1) SI1937065T1 (ar)
TW (1) TWI414510B (ar)
UY (1) UY29791A1 (ar)
WO (1) WO2007033231A2 (ar)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG145752A1 (en) 2003-09-19 2008-09-29 Janssen Pharmaceutica Nv 4-((phenoxyalkyl)thio)-phenoxyacetic acids and analogs
KR101094742B1 (ko) * 2003-09-19 2011-12-16 얀센 파마슈티카 엔.브이. 4-((페녹시알킬)티오)-페녹시아세트산 및 유사체
MY147518A (en) * 2004-09-15 2012-12-31 Janssen Pharmaceutica Nv 4-((phenoxyalkyl)thio)-phenoxyacetic acids and analogs
JO3006B1 (ar) * 2005-09-14 2016-09-05 Janssen Pharmaceutica Nv املاح ليسين مبتكرة من مشتقات حامض 4-((فينوكسي الكيل)ثيو) فينوكسي الخليك
UY30288A1 (es) * 2006-04-18 2007-08-31 Janssen Pharmaceutica Nv Derivados del ácido benzoazepin-oxi-acético como agonistas de ppar-delta usados para aumentar hdl-c. reducir ldl-c y reducir colesterol
CA2740874C (en) 2008-10-17 2018-02-27 Metabolex, Inc. Use of ppar.gamma.agonists to reduce small dense ldl particles
ES2650665T3 (es) 2009-07-31 2018-01-19 Grünenthal GmbH Método de cristalización y biodisponibilidad
US20160016982A1 (en) * 2009-07-31 2016-01-21 Thar Pharmaceuticals, Inc. Crystallization method and bioavailability
PL2531200T3 (pl) * 2010-02-06 2017-10-31 Gruenenthal Gmbh Sposób krystalizacji i biodostępność
EP2612669A4 (en) 2010-08-31 2014-05-14 Snu R&Db Foundation USING THE FÖTAL REPROGRAMMING OF A PPAR AGONIST
WO2012071517A2 (en) 2010-11-24 2012-05-31 Thar Pharmaceuticals, Inc. Novel crystalline forms
US20160279085A1 (en) * 2013-11-20 2016-09-29 Cymabay Therapeutics, Inc. Treatment of Severe Hyperlipidemia
US20150139987A1 (en) 2013-11-20 2015-05-21 Cymabay Therapeutics, Inc. Treatment of homozygous familial hypercholesterolemia
US10272058B2 (en) 2014-03-20 2019-04-30 Cymabay Therapeutics, Inc. Treatment of intrahepatic cholestatic diseases
KR102000332B1 (ko) * 2014-03-20 2019-07-15 사이머베이 쎄라퓨틱스, 인코퍼레이티드 간내 담즙정체성 질환의 치료
NZ724740A (en) * 2014-04-11 2019-11-29 Cymabay Therapeutics Inc Treatment of nafld and nash
MX2016017081A (es) * 2014-06-26 2017-05-01 Cymabay Therapeutics Inc Tratamiento de hipertrigliceridemia grave.
EP3476835A4 (en) * 2016-05-16 2020-01-01 GB001, Inc. QUINOLEIN DERIVATIVE CRYSTAL
US10512622B2 (en) 2017-07-14 2019-12-24 Cymabay Therapeutics, Inc. Treatment of intrahepatic cholestatic diseases
US20190076500A1 (en) 2017-09-13 2019-03-14 Novartis Ag Combinations comprising fxr agonists
LT3973959T (lt) 2017-09-26 2025-01-10 Cymabay Therapeutics, Inc. Cholestazinio niežulio gydymas seladelparu
BR112021009038A2 (pt) 2018-11-16 2021-08-10 Cymabay Therapeutics, Inc. tratamento combinado de nafld e nash
MX2021005725A (es) * 2018-11-16 2021-07-21 Cymabay Therapeutics Inc Tratamiento de la obesidad y sus complicaciones.
US20230008367A1 (en) 2019-09-26 2023-01-12 Abionyx Pharma Sa Compounds useful for treating liver diseases
US20210145774A1 (en) * 2019-11-14 2021-05-20 Cymabay Therapeutics, Inc. Treatment of alcoholic liver disease
US20210145775A1 (en) 2019-11-14 2021-05-20 Cymabay Therapeutics, Inc. Treatment of intestinal barrier dysfunction and associated diseases
CN112824380B (zh) * 2019-11-21 2024-11-29 杭州百诚医药科技股份有限公司 α-氟代查耳酮类衍生物及其应用
JP7596548B2 (ja) 2021-02-01 2024-12-09 サイマベイ・セラピューティクス・インコーポレイテッド 胆管症の治療
WO2022189856A1 (en) 2021-03-08 2022-09-15 Abionyx Pharma Sa Compounds useful for treating liver diseases
WO2024159048A1 (en) 2023-01-29 2024-08-02 Cymabay Therapeutics, Inc. Treatment of uremic pruritus
WO2024159051A1 (en) 2023-01-29 2024-08-02 Cymabay Therapeutics, Inc. Treatment of chronic pruritic dermatoses
CN118546109A (zh) * 2023-02-24 2024-08-27 哈尔滨三联药业股份有限公司 含氮杂环类化合物及其医药用途

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2460689C3 (de) * 1974-12-20 1980-06-26 Klinge Pharma Gmbh & Co, 8000 Muenchen 13-disubstituierte Propanol-(2)-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
US4125732A (en) * 1977-05-06 1978-11-14 American Cyanamid Company 2-Aryloxy-2-(phenoxyalkoxy)phenyl acetic acid and esters
DE3026924A1 (de) 1980-07-16 1982-02-18 Klinge Pharma GmbH & Co, 8000 München 1,3-diphenoxypropan-2-ol-derivate sowie verfahren zu ihrer herstellung und diese enthaltende arzneimittel
DE3028776A1 (de) 1980-07-29 1982-02-25 Klinge Pharma GmbH & Co, 8000 München Neue 1,3-diphenoxypropan-2-on-derivate sowie verfahren zu ihrer herstellung und diese enthaltende arzneimittel
DE3169761D1 (en) 1981-01-09 1985-05-09 Fisons Plc Phenoxy- and thiophenoxy compounds, methods for their preparation and pharmaceutical formulations containing them
JPS58177934A (ja) 1982-04-13 1983-10-18 Takeda Chem Ind Ltd ベンゾキノン誘導体
ATE22072T1 (de) 1982-09-30 1986-09-15 Merck Frosst Canada Inc Leukotrienantagonisten, deren herstellung und diese enthaltende zusammensetzungen.
US4820867A (en) 1983-04-21 1989-04-11 Merck Frosst Canada, Inc. Phenoxypropoxy halophenylacetic acids as leukotriene antagonists
US4513006A (en) 1983-09-26 1985-04-23 Mcneil Lab., Inc. Anticonvulsant sulfamate derivatives
JPS61268651A (ja) 1985-05-23 1986-11-28 Takeda Chem Ind Ltd フエニル酢酸誘導体およびその製造法
EP0204349A3 (de) 1985-06-01 1990-01-03 Dr. Karl Thomae GmbH Neue heteroaromatische Aminderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
JPH0714910B2 (ja) * 1988-12-13 1995-02-22 塩野義製薬株式会社 安定な結晶性の塩およびそれを含有するトロンボキサン受容体拮抗剤
US5487008A (en) * 1990-04-20 1996-01-23 The Regents Of The University Of Michigan Method and system for detecting the misfire of a reciprocating internal combustion engine in frequency domain
CA2092152A1 (en) * 1992-03-23 1993-09-24 Azuma Igarashi Phenoxyacetic acid compounds and medical preparations containing them
US5726165A (en) * 1994-07-29 1998-03-10 Smithkline Beecham P.L.C. Derivatives of 4-(2-aminoethyl)phenoxymethyl-phosphonic and -phosphinic acid and pharmaceutical and veterinary uses therefor
DE69733154T2 (de) 1996-02-02 2006-03-09 Merck & Co., Inc. Verfahren zur behandlung von diabetes und verwandter krankheitszustände.
AU721452B2 (en) 1996-02-02 2000-07-06 Merck & Co., Inc. Antidiabetic agents
JP3268242B2 (ja) 1996-11-14 2002-03-25 三共株式会社 縮合複素環化合物を含有する医薬
JP4427825B2 (ja) 1997-07-24 2010-03-10 アステラス製薬株式会社 コレステロール低下作用を有する医薬組成物
GB9914977D0 (en) 1999-06-25 1999-08-25 Glaxo Group Ltd Chemical compounds
GB0031107D0 (en) 2000-12-20 2001-01-31 Glaxo Group Ltd Chemical compounds
NZ529351A (en) * 2001-06-07 2006-01-27 Lilly Co Eli Modulators of peroxisome proliferator activated receptors
EP1414778A1 (en) 2001-07-30 2004-05-06 Novo Nordisk A/S Novel vinyl carboxylic acid derivatives and their use as antidiabetics etc.
BRPI0211844B8 (pt) 2001-08-10 2021-05-25 Nippon Chemiphar Co composto de ácido fenóxi-acético ou um de seus sais farmaceuticamente aceitáveis, e, composição farmacêutica
BRPI0213243B8 (pt) 2001-10-12 2021-05-25 Nippon Chemiphar Co composto heterocíclico aromático contendo um anel oxazol, tiazol ou imidazol, ou um sal farmaceuticamente aceitável do mesmo, e, composição farmacêutica
ITRM20020014A1 (it) 2002-01-15 2003-07-15 Sigma Tau Ind Farmaceuti Derivati di acidi a-feniltiocarbossilici e a-fenilossicarbossilici utili per il trattamento di patologie che rispondono all'attivazione del
EP1480957A1 (en) 2002-03-01 2004-12-01 Smithkline Beecham Corporation Hppars activators
US6875780B2 (en) * 2002-04-05 2005-04-05 Warner-Lambert Company Compounds that modulate PPAR activity and methods for their preparation
GB0214149D0 (en) 2002-06-19 2002-07-31 Glaxo Group Ltd Chemical compounds
WO2004022533A1 (en) 2002-09-05 2004-03-18 Novo Nordisk A/S Novel vinyl carboxylic acid derivatives and their therapeutical use
DE60333211D1 (de) * 2002-10-28 2010-08-12 High Point Pharmaceuticals Llc Neue verbindungen und deren verwendung als ppar-modulatoren
MXPA05004405A (es) * 2002-10-28 2005-07-05 Novo Nordisk As Compuestos novedosos utiles en el tratamiento de enfermedades mediadas por ppar.
US7494805B2 (en) 2003-02-14 2009-02-24 Biogen Idec Ma Inc. Expression cassette and vector for transient or stable expression of exogenous molecules
EP1660428A1 (en) 2003-08-20 2006-05-31 Eli Lilly And Company Ppar modulators
KR101094742B1 (ko) * 2003-09-19 2011-12-16 얀센 파마슈티카 엔.브이. 4-((페녹시알킬)티오)-페녹시아세트산 및 유사체
SG145752A1 (en) 2003-09-19 2008-09-29 Janssen Pharmaceutica Nv 4-((phenoxyalkyl)thio)-phenoxyacetic acids and analogs
UA84035C2 (ru) 2003-10-31 2008-09-10 Янссен Фармацевтика Н.В. Производные феноксиуксусных кислот, полезные как двойные агонисты активированных рецепторов пероксисомального пролифератора (ppar)
CA2563635A1 (en) 2004-04-21 2005-11-03 Schering Corporation Pyrazolo-[4,3-e]-1,2,4-triazolo-[1,5-c]-pyrimidine adenosine a2a receptor antagonists
RU2384565C2 (ru) * 2004-07-01 2010-03-20 Ф.Хоффманн-Ля Рош Аг Фенильные производные, содержащие ацетиленовую группу
PE20060664A1 (es) 2004-09-15 2006-08-04 Novartis Ag Amidas biciclicas como inhibidores de cinasa
MY145712A (en) * 2004-09-15 2012-03-30 Janssen Pharmaceutica Nv 4-((phenoxyalkyl)thio)-phenoxyacetic acids and analogs
MY147518A (en) 2004-09-15 2012-12-31 Janssen Pharmaceutica Nv 4-((phenoxyalkyl)thio)-phenoxyacetic acids and analogs
JO3006B1 (ar) * 2005-09-14 2016-09-05 Janssen Pharmaceutica Nv املاح ليسين مبتكرة من مشتقات حامض 4-((فينوكسي الكيل)ثيو) فينوكسي الخليك
GB0618963D0 (en) * 2006-09-26 2006-11-08 Ucl Business Plc Formulations and composites with reactive fillers

Also Published As

Publication number Publication date
HUE025185T2 (en) 2016-02-29
KR20150013952A (ko) 2015-02-05
UY29791A1 (es) 2006-12-29
AU2006291006B2 (en) 2012-09-13
ES2535427T3 (es) 2015-05-11
JP2009514797A (ja) 2009-04-09
TWI414510B (zh) 2013-11-11
KR20180079468A (ko) 2018-07-10
CN101304656A (zh) 2008-11-12
TW200804256A (en) 2008-01-16
EP1937065B1 (en) 2015-01-28
JP5467770B2 (ja) 2014-04-09
GT200600420A (es) 2007-05-08
US20110105616A1 (en) 2011-05-05
PL1937065T3 (pl) 2015-07-31
HK1122699A1 (en) 2009-05-29
US8669288B2 (en) 2014-03-11
PT1937065E (pt) 2015-03-04
AR058044A1 (es) 2008-01-23
US20070060649A1 (en) 2007-03-15
BRPI0615835B1 (pt) 2020-04-22
CN101304656B (zh) 2013-03-13
KR20080046695A (ko) 2008-05-27
KR20160079129A (ko) 2016-07-05
SI1937065T1 (sl) 2015-05-29
BRPI0615835A2 (pt) 2011-05-31
WO2007033231A3 (en) 2007-10-11
WO2007033231A2 (en) 2007-03-22
BRPI0615835B8 (pt) 2021-05-25
KR20130100800A (ko) 2013-09-11
EP1937065A4 (en) 2010-07-21
AU2006291006A1 (en) 2007-03-22
CA2622722A1 (en) 2007-03-22
EP1937065A2 (en) 2008-07-02
PE20070434A1 (es) 2007-05-14
NZ566504A (en) 2010-11-26
HN2006032171A (es) 2011-03-15
CA2622722C (en) 2016-04-19
DK1937065T3 (en) 2015-02-09
US7709682B2 (en) 2010-05-04

Similar Documents

Publication Publication Date Title
JO3006B1 (ar) املاح ليسين مبتكرة من مشتقات حامض 4-((فينوكسي الكيل)ثيو) فينوكسي الخليك
CY1112853T1 (el) Ενδιαμεση ενωση 4-(ακετυλαμινο)-3-[(4-χλωροφαινυλ)θειο]-2-μεθυλ-1η-ινδολη-1-οξικο οξυ αιθυλεστερα
WO2007071766A3 (en) Phenoxy acetic acids as ppar delta activators
NZ601866A (en) Alkynyl phenyl derivative compounds for treating ophthalmic diseases and disorders
ME00152B (me) Nove farmaceutske kompozicije 4-(4-(3-(4-hlor0 -3-trifluorometil-fenil)-ureid0)-3-fluoro-fenoksi)piridin-2-karbonska kiseline za lečenje hiper-prolifera tivnih poremećaja
NO20055370L (no) Alfa-substituert karboksylsyre som PPAR modulatorer
WO2005018529A3 (en) Phenoxiacetic acid derivatives
DK1184366T3 (da) Substituerede phenylpropionsyrederivater som agonister for human perioxisomproliferatoraktiveret receptor alpha(PPAR)
MX2011009244A (es) Derivado de piridina.
WO2008019967A3 (en) Phenyl, pyridine and quinoline derivatives
MX2009012371A (es) Metabolitos de derivados de (tio)-carbamoil-ciclohexano.
MX2012007030A (es) Derivados de acido carboxilico de pirrolidina o tiazolidina, composicion farmaceutica y metodos para su uso en el tratamiento de transtornos metabolicos, como agonistas del receptor 43 acoplado por proteina-g (gpr43).
TW200700069A (en) Benzothiazole, thiazolopyridine, benzooxazole and oxazolopyridine derivatives
PH12014500997B1 (en) 3,4-di-substituted pyridine compound, methods of using and compositions comprising the same
WO2007041076A3 (en) 1,2,3,5-tetrahydro-cyclopental[c]quinolin-4-one derivatives as rxr agonists for the treatment of dyslipidemia, hypercholesterolemia and diabetes
MA32455B1 (ar) أوكسازولوبيريميديني كمنبهات مستقبلات edg -1
UA99109C2 (ru) Производные пиперидин- или пиперазинзамещенной тетрагидронафталин-1-карбоновой кислоты, ингибирующие mtp
WO2007129066A8 (en) 4- (2,6-dichloro-benzoylamino) -1h-pyrazole-3-carboxylic acid (1-methanesulphonyl-piperidin-4-yl) -amide for the treatment of cancer
CL2024000758A1 (es) Sal de trometamina de ácido 2-[4-[(5,6-difenilpirazin-2-il)-propan-2-ilamino]butoxi]acético
WO2005115383A3 (en) Substituted triazoles as modulators of ppar and methods of their preparation
WO2023078333A8 (zh) 一种取代的苯丙酸衍生物及其用途
MX2010007426A (es) Composiciones farmaceuticas para tratar trastorno del higado graso.
MXPA05008951A (es) Derivados de acido 3-metil -2-(3- (2-fenil -oxazol-4 -ilmetoxi) -ciclohexanocarbonil -aminobutirico y compuestos relacionados como moduladores de ppar para el tratamiento de diabetes de tipo 2 y aterosclerosis.
NO20051011L (no) Kirale oksazol-arylpropionsyrederivater og anvendelse derav som PPAR agonister
BRPI0510278A (pt) método para produzir compostos, produto, e, composto